ReviewInternational journal of nanomedicine2025
Nanozymes Targeting Redox Imbalance: A Novel Weapon for Immunomodulation and Organ Protection in Sepsis.
Review in International journal of nanomedicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Pathological Signal-Responsive Nanoplatforms for Sepsis: Integrating Biomarker Sensing With Spatiotemporal Drug Delivery and Immunomodulation.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Review
- Autophagy-ferroptosis crosstalk in sepsis: metabolic pathways, redox injury, and host-directed antioxidant nanomedicine.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Sepsis remains a major challenge in critical care, with high mortality despite ongoing improvements in treatment. The early uncontrolled burst of reactive oxygen and nitrogen species (RONS) and cytokine storms form a vicious cycle, ultimately leading to multiple organ dysfunction syndrome (MODS). The absence of effective therapies to interrupt this process is likely a key reason for poor outcomes. In recent years, the emergence of nanozymes has represented a transformative breakthrough in addressing this challenge. With strong antioxidant capacity, high stability, and low cost, nanozymes surpass conventional antioxidants and offer a promising therapeutic strategy for sepsis, especially through effective redox regulation. Nanozymes not only efficiently scavenge diverse RONS but also inhibit hyperactivated inflammatory pathways, thereby breaking the fatal vicious cycle between oxidative stress and cytokine storms. This provides a novel approach for immunomodulation and organ protection in sepsis. This review summarizes the key role of redox imbalance in sepsis progression and the therapeutic potential of nanozymes targeting redox imbalance, discusses their in vivo metabolic distribution and biosafety, and outlines prospects for future clinical translation and development. The objective is to provide insights that facilitate the development of innovative therapies targeting the RONS-inflammation axis in sepsis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.